Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence
Gilles Montalescot, David Brieger, Anthony J Dalby, Seung-Jung Park, Roxana Mehran, Gilles Montalescot, David Brieger, Anthony J Dalby, Seung-Jung Park, Roxana Mehran
Abstract
The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.
Keywords: P2Y(12) inhibitors; antiplatelet therapy; aspirin; coronary stent; drug-eluting stent.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed